Xinlitan (allisartan) / Allist - LARVOL DELTA

Antihypertensive drugs for hyperuricemia in patients with hypertension: a systematic review and network meta-analysis of Chinese trials. (PubMed, BMC Cardiovasc Disord) - "Based on the only available eligible evidence, the combination of losartan and amlodipine was the optimal dual therapy for Chinese patients with hypertension and hyperuricemia, while allisartan and losartan were the most effective monotherapies for lowering serum uric acid. These findings are not generalizable to non-Chinese populations, reflecting a gap in global evidence rather than intentional study scope restriction."

Journal • Retrospective data • Review • Cardiovascular • Hypertension

SHOT: Sacubitril/Allisartan for Hypertensive Patients With Overweight or Obesity (clinicaltrials.gov) - P4 | N=104 | Not yet recruiting | Sponsor: Jing Liu

New P4 trial • Cardiovascular • Genetic Disorders • Hypertension • Obesity

Promising efficacy of alisartan isoproxil combined with probiotics in elderly hypertensive patients and analysis of cardiovascular prognostic factors. (PubMed, Am J Transl Res) - "Alisartan isoproxil combined with probiotics effectively improves blood pressure, inflammatory markers, blood lipids, and vascular endothelial function in elderly hypertensive patients. Age, BMI, SBP, and DBP are identified as risk factors for MACE and should be addressed early with preventive interventions."

Biomarker • Journal • Cardiovascular • Hypertension • EDN1

Effects of Two Allisartan Isoproxil-Based Antihypertensive Therapies on Sexual Function and Blood Pressure in Male Hypertensive Patients: A Single-Center, Open-Label, and Randomized Controlled Trial. (PubMed, J Clin Hypertens (Greenwich)) - "This study evaluated the effects of allisartan isoproxil combined with amlodipine besylate tablets (Group A+C) or metoprolol succinate extended-release tablets (Group A+B) on sexual function and nighttime blood pressure (nBP) in 130 male patients with essential hypertension (EH). It was concluded that combined antihypertension of allisartan isoproxil with amlodipine besylate tablets improved sexual function in male hypertensive patients in terms of the ITS, IS, OF, and OS, but there was no significant improvement in EF and SD. Both combined antihypertensive regimens were effective in lowering BP, but allisartan isoproxil combined with amlodipine besylate tablets demonstrated more advantageous in lowering DBP and nBP."

Clinical • Journal • Cardiovascular • Hypertension

Pharmacokinetic Study of Allisartan Isoproxil Tablets in Healthy Chinese Participants (clinicaltrials.gov) - P4 | N=54 | Recruiting | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P4 trial

Sacubitril/Allisartan in hyperuricemia (ESC-WCC 2025) - No abstract available

Late-breaking abstract • Cardiovascular • Hypertension

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese With Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Active, not recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Trial primary completion date: Dec 2026 ➔ Sep 2026

Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension

Antihypertensive potential of diosgenin: A comparative pharmacoinformatics study. (PubMed, Comput Biol Med) - "This study explores the antihypertensive potential of thirty-six natural terpenoids targeting the AT1R, with Allisartan isoproxil (active form, LCA) used as a positive control...Additionally, PPI network and hub genes analysis identified potential molecular targets for Diosgenin, including SRC, ABL1, IGF1R, and JAK2, suggesting possible mechanistic role. Diosgenin is a promising natural therapeutic candidate for hypertension treatment, which could regulate vascular function, smooth muscle cell activity, and endothelial function via various mechanisms by influencing IGF1R, JAK2, KIT, MDM2, MET, and IL2 demonstrated through KEGG pathway analysis."

Journal • Cardiovascular • Hypertension • ABL1 • IL2 • JAK2

A correlative study of the effect of allisartan isoproxil on sexual function and nocturnal blood pressure in male patients with mild to moderate hypertension (ChiCTR) - P4 | N=111 | Completed | Sponsor: Lanzhou University Second Hospital; Lanzhou University Second Hospital

New P4 trial • Cardiovascular • Hypertension

Effects of Allisartan on Uric Acid, Left Atrial, Left Ventricular, and Artery Stiffness in Mild-to-Moderate Essential Hypertension. (PubMed, J Clin Hypertens (Greenwich)) - "In Conclusion, allisartan 240 mg and olmesartan 20 mg once daily achieve broadly similar reductions in blood pressure, improving left heart structure and function, mitigating arterial stiffness in individuals with mild-to-moderate essential hypertension. Compared to olmesartan, allisartan demonstrates significant reductions in serum UA."

Clinical • Journal • Cardiovascular • Hypertension

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients with Essential Hypertension: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomised study. (PubMed, J Hum Hypertens) - "AML/ALI combination was generally safe and well tolerated, with sustained efficacy up to 52 weeks. The study concluded that ALI/AML offers a convenient, single-pill option for effective BP reduction in hypertensive patients."

Journal • P3 data • Review • Acute Myelogenous Leukemia • Cardiovascular • Hypertension

Blood pressure-lowering efficacy of Sacubitril/Allisartan versus Olmesartan in Chinese hypertensive patients with a nondipping blood pressure pattern. (PubMed, J Hypertens) - "Sacubitril/Allisartan is particularly effective in reducing nighttime blood pressure and in reversing the nondipping to dipping nighttime blood pressure pattern."

Clinical • Journal • Cardiovascular • Hypertension

Local structural dynamics and vibrational energy transfer in an angiotensin receptor-neprilysin inhibitor by ultrafast 2D IR spectroscopy. (PubMed, J Chem Phys) - "As a novel drug-drug cocrystal, sacubitril allisartan calcium (S086) has demonstrated significant efficacy in the treatment of hypertension and heart failure...Vibrational energy transfer between the bidentate and tridentate COO- groups in the α-crystal was found to be faster than that in the ξ-crystal, suggesting shorter intermolecular distances between EXP3174 and sacubitril in the former. These findings provide dynamical structural parameters that help to understand the stability and releasing mechanisms of the drug molecules."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Hypertension

Bioequivalence Study of Single Oral Dose of Allisartan Isoproxil and Amlodipine Besylate Tablets in Healthy Subjects under Fasting Conditions (ChiCTR) - P1 | N=50 | Sponsor: Second Affiliated Hospital of Guangzhou Medical University; Second Affiliated Hospital of Guangzhou Medical University

New P1 trial • Cardiovascular • Hypertension

Efficacy and Safety of Allisartan Isoproxil/Amlodipine in Patients With Essential Hypertension Uncontrolled by Amlodipine: A Phase III, Multicenter, Double-Blind, Parallel-Group, Randomized Controlled Trial. (PubMed, J Clin Hypertens (Greenwich)) - P3 | "This once-daily single-pill combination demonstrated promising efficacy and tolerability. Trial Registration: ClinicalTrials.gov identifier: NCT06465264."

Clinical • Journal • P3 data • Acute Myelogenous Leukemia • Cardiovascular • Hypertension

ANTI-MASK: Antihypertensive Treatment in Masked Hypertension (clinicaltrials.gov) - P4 | N=320 | Completed | Sponsor: Yan Li | Active, not recruiting ➔ Completed

Trial completion • Cardiovascular • Hypertension

Intensive Management of Blood Pressure and Cholesterol in Elderly Chinese with Hypertension and Atrial Fibrillation (clinicaltrials.gov) - P4 | N=1200 | Active, not recruiting | Sponsor: Shanghai Jiao Tong University School of Medicine | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Dec 2025 ➔ Dec 2026

Enrollment closed • Trial completion date • Trial primary completion date • Atrial Fibrillation • Cardiovascular • Hypertension

Coexistence of Fabry Disease and Membranous Nephropathy: A Case Report. (PubMed, Iran J Kidney Dis) - "Treatment with ramipril turned urine protein negative. The patient was being treated with allisartan isoproxil. However, at the time, the urine protein did not turn negative."

Journal • Fabry Disease • Genetic Disorders • Glomerulonephritis • Renal Disease

Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension. (PubMed, JACC Asia) - "Sacubitril/allisartan was well tolerated, and no cases of angioedema or death were reported. Sacubitril/allisartan is effective for the treatment of hypertension and well tolerated in Chinese patients."

Clinical • Journal • Cardiovascular • Hypertension

Antihypertensive treatment of masked hypertension guided by ambulatory blood pressure monitoring: a double-blind, placebo-controlled trial (ESC 2024) - "Active antihypertensive treatment consisted of allisartan starting at 80 mg/day to be increased to 160 mg/day at month 2 and to be combined with amlodipine 2.5 mg/day at month 4, if the ambulatory BP remained uncontrolled... Masked hypertensive patients require antihypertensive treatment guided by out-of-office BP monitoring before subclinical TOD progresses to major cardiovascular complications."

Clinical • Cardiovascular • Hypertension

Efficacy of antihypertensive treatment for target organ protection in patients with masked hypertension (ANTI-MASK): a multicentre, double-blind, placebo-controlled trial. (PubMed, EClinicalMedicine) - P4 | "Active treatment consisted of allisartan starting at 80 mg/day, to be increased to 160 mg/day at month 2, and to be combined with amlodipine 2.5 mg/day at month 4, if the ambulatory BP remained uncontrolled...However, the long-term benefit in preventing cardiovascular complications still needs to be established. Salubris China."

Journal • Cardiovascular • Diabetic Nephropathy • Hypertension • Nephrology • Renal Disease

To Assess Allisartan Isoproxil/Sustained-Release Indapamide in Patients With Essential Hypertension Uncontrolled With Allisartan Isoproxil (clinicaltrials.gov) - P3 | N=366 | Completed | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P3 trial • Cardiovascular • Hypertension

Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis. (PubMed, Front Cardiovasc Med) - "These benefits are achieved with minimal adverse reactions. https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023467869, identifier PROSPERO CRD42023467869."

Journal • Retrospective data • Review • Cardiovascular • Hypertension

To Assess Allisartan Isoproxil/Amlodipine Tablets in Patients With Essential Hypertension Uncontrolled With Amlodipine or Allisartan Isoproxil (clinicaltrials.gov) - P3 | N=499 | Completed | Sponsor: Shenzhen Salubris Pharmaceuticals Co., Ltd.

New P3 trial • Cardiovascular • Hypertension

Efficacy of angiotensin receptor blockers for nocturnal blood pressure reduction: a systematic review and meta-analysis. (PubMed, Ann Med) - "Additionally, allisartan showed improvement effect in the proportion of patients with dipping BP pattern. This study demonstrates that for patients with mild to moderate hypertension, allisartan, olmesartan and telmisartan have more advantages in nocturnal BP reduction among the ARBs, while allisartan can reduce nighttime BP more than daytime BP and improve the dipping pattern."

Clinical • Journal • Retrospective data • Review • Cardiovascular • Hypertension